MA30966B1 - Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3 - Google Patents

Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3

Info

Publication number
MA30966B1
MA30966B1 MA31946A MA31946A MA30966B1 MA 30966 B1 MA30966 B1 MA 30966B1 MA 31946 A MA31946 A MA 31946A MA 31946 A MA31946 A MA 31946A MA 30966 B1 MA30966 B1 MA 30966B1
Authority
MA
Morocco
Prior art keywords
combination
inhibitors
iap
flt3
active agents
Prior art date
Application number
MA31946A
Other languages
English (en)
Inventor
James Douglas Griffin
Leigh Zawel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30966B1 publication Critical patent/MA30966B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES COMBINAISONS D'INHIBITEURS DE IAP ET D'INHIBITEURS DE FLT3, DES COMPOSITIONS PHARMACOLOGIQUES COMPRENANT UNE TELLE COMBINAISON, DES PROCÉDÉS DE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES, NOTAMMENT LA LEUCÉMIE AIGUË MYÉLOÏDE (LAM). LES COMPOSITIONS PHARMACOLOGIQUES DE L'INVENTION COMPRENNENT UN COMPOSÉ INHIBANT LA LIAISON DE LA PROTÉINE SMAC (ACTIVATEUR DE CASPASE DÉRIVÉ DE MITOCHONDRIES DITES SECONDAIRES) À L'INHIBITEUR D'APOPTOSE (INHIBITEUR DE IAP) COMBINÉ À AU MOINS UN PRINCIPE PHARMACEUTIQUEMENT ACTIF. L'INVENTION CONCERNE ÉGALEMENT L'UTILISATION DE CES COMBINAISONS POUR TRAITER UNE LEUCÉMIE AIGUË MYÉLOÏDE. L'INVENTION CONCERNE ENCORE UN CONDITIONNEMENT COMMERCIAL CONTENANT CETTE COMBINAISON.
MA31946A 2006-11-28 2009-06-03 Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3 MA30966B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US89108807P 2007-02-22 2007-02-22

Publications (1)

Publication Number Publication Date
MA30966B1 true MA30966B1 (fr) 2009-12-01

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31946A MA30966B1 (fr) 2006-11-28 2009-06-03 Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3

Country Status (20)

Country Link
US (1) US8492429B2 (fr)
EP (1) EP2089024B1 (fr)
JP (1) JP5394249B2 (fr)
KR (1) KR20090087094A (fr)
AT (1) ATE509629T1 (fr)
AU (1) AU2007325280B2 (fr)
BR (1) BRPI0719543A2 (fr)
CA (1) CA2670498A1 (fr)
CO (1) CO6210722A2 (fr)
EC (1) ECSP099472A (fr)
GT (1) GT200900142A (fr)
IL (1) IL198551A0 (fr)
MA (1) MA30966B1 (fr)
MX (1) MX2009005621A (fr)
NO (1) NO20092417L (fr)
PL (1) PL2089024T3 (fr)
PT (1) PT2089024E (fr)
RU (1) RU2456983C2 (fr)
TN (1) TN2009000206A1 (fr)
WO (1) WO2008067280A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007048224A1 (fr) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Composés de liaison au domaine iap bir
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CN102099035A (zh) * 2008-05-16 2011-06-15 诺瓦提斯公司 Iap抑制剂的免疫调节
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015109391A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polythérapie anticancéreuse à base de smc
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
WO2021220178A1 (fr) 2020-04-29 2021-11-04 Cominnex Zrt. Antagonistes d'iap et leurs applications thérapeutiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
WO2004005248A1 (fr) 2002-07-02 2004-01-15 Novartis Ag Inhibiteurs peptidiques de la liaison de la proteine smac avec les proteines inhibitrices de l'apoptose (iap)
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
KR20080080131A (ko) * 2005-12-20 2008-09-02 노파르티스 아게 Ｉａｐ-억제제와 탁산의 조합물
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
EP2089024A2 (fr) 2009-08-19
KR20090087094A (ko) 2009-08-14
US8492429B2 (en) 2013-07-23
CO6210722A2 (es) 2010-10-20
JP5394249B2 (ja) 2014-01-22
AU2007325280B2 (en) 2011-03-10
PT2089024E (pt) 2011-08-31
CA2670498A1 (fr) 2008-06-05
EP2089024B1 (fr) 2011-05-18
PL2089024T3 (pl) 2011-10-31
ECSP099472A (es) 2009-10-30
RU2456983C2 (ru) 2012-07-27
RU2009124590A (ru) 2011-01-10
JP2010511059A (ja) 2010-04-08
ATE509629T1 (de) 2011-06-15
IL198551A0 (en) 2010-02-17
TN2009000206A1 (en) 2010-10-18
MX2009005621A (es) 2009-06-12
WO2008067280A2 (fr) 2008-06-05
NO20092417L (no) 2009-08-25
WO2008067280A3 (fr) 2008-08-07
GT200900142A (es) 2010-06-24
AU2007325280A1 (en) 2008-06-05
US20100056467A1 (en) 2010-03-04
BRPI0719543A2 (pt) 2014-02-25

Similar Documents

Publication Publication Date Title
MA30966B1 (fr) Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3
MX2009005551A (es) Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
MX2009006877A (es) Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
EP2526934A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
ZA200701629B (en) Gyrase inhibitors and uses thereof
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2007044325A3 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
EA200900552A1 (ru) Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
WO2021080188A3 (fr) Composition pour la prévention ou le traitement de la dépression comprenant un inhibiteur d'expression de protéines et son utilisation
WO2006091222A3 (fr) Methodes de traitement et de prevention du syndrome respiratoire aigu severe (sars) au moyen de avr118
AR062215A1 (es) Inhibidor de trombina activo por via oral
AU2016219620A1 (en) Compositions and methods useful for treatment of respiratory illness